Status:
COMPLETED
Real-world Effectiveness and Cost-effectiveness of Leading Inhaled Corticosteroids in Asthma Management
Lead Sponsor:
Research in Real-Life Ltd
Collaborating Sponsors:
Teva Branded Pharmaceutical Products R&D, Inc.
Conditions:
Asthma
Eligibility:
All Genders
5-60 years
Brief Summary
The objective of the study was to compare the effectiveness, cost-effectiveness and direct healthcare costs of managing asthma in patients with evidence of persistent asthma, following the initiation ...
Detailed Description
While current UK asthma guidelines are underpinned with evidence from RCTs, much of this evidence has been undertaken in patients who are not representative of the majority of the current UK asthma po...
Eligibility Criteria
Inclusion
- Included patients must:
- aged 5-60 years
- evidence of asthma: a diagnostic code of asthma or ≥2 prescriptions for asthma in baseline year at different points in time including one of ICS
- on current therapy at the IPD, defined as ≥1 ICS script and ≥1 other asthma prescriptions in the 12 months prior to first change in therapy
- had definite dosing instructions
- have at least 1 year of up-to-standard (UTS) baseline data before IPD
- have at least 1 year of UTS outcome data after IPD.
Exclusion
- had a diagnostic read code for chronic obstructive pulmonary disease (COPD) at any time
- had a diagnostic read code for chronic respiratory disease at any time
- For the therapy increase patient cohort, any patients receiving a combination inhaler in addition to their separate ICS inhaler in the year prior to IPD were also excluded.
Key Trial Info
Start Date :
January 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
815377 Patients enrolled
Trial Details
Trial ID
NCT01141439
Start Date
January 1 2001
End Date
July 1 2010
Last Update
March 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Practice Research Database
London, London, United Kingdom, SW8 5NQ